# AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

> **NCT07454642** · PHASE1 · RECRUITING · sponsor: **Avacta Life Sciences Ltd** · enrollment: 144 (estimated)

## Conditions studied

- Vulvar Adenocarcinoma
- PDAC - Pancreatic Ductal Adenocarcinoma
- Gastric Adenocarcinoma
- GEJ Adenocarcinoma
- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Small Cell Carcinoma of Lung

## Interventions

- **DRUG:** AVA6103

## Key facts

- **NCT ID:** NCT07454642
- **Lead sponsor:** Avacta Life Sciences Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2029-01
- **Final completion:** 2030-06
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07454642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07454642, "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07454642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*